- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Strides Pharma reported 13% YoY revenue growth to ₹1,265.4 Cr, driven by strong 17% growth in Ex-US markets. EBITDA rose 5.4% to ₹229.8 Cr. Operational PAT hit ₹123.1 Cr. The company also reduced net debt by ₹11.9 Cr and divested Pivot Path, unlocking ₹100 Cr.